RNA-based therapies that enable tissue-specific delivery are currently being tested in clinical trials.31 Our study provides a rationale for testing vascular endothelium-targeted delivery platforms with FABP4 siRNA to inhibit tumour growth. Here, FABP4 is linked to neoplasm.